The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be ∼ 20-70%. However, many of these studies are limited by different study designs and small sample sizes. Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN + RBV) in a systematic and quantitative manner. A comprehensive literature search in MEDLINE and EMBASE for 'genotype 4' was conducted in November 2013. Abstracts from American Association for the Study of Liver Diseases, Asian Pacific Study of the Liver, Digestive Disease Week, and European Association for the Study of the Liver in 2012/2013 were reviewed. Inclusion criteria were original studies with at least 25 treatmentnaive HCV-4 patients treated with PEG IFN + RBV. Exclusion criteria were coinfection with HIV, hepatitis B virus, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (P < 0.05) and I 2 statistic (>50%). We included 51 studies (11 102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% [95% confidence interval (CI): 50-55%] (Q-statistic = 269.20, P < 0.05; I 2 = 81.43).
Background
Hepatitis C virus (HCV) is one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide, chronically infecting an estimated 170 million people globally [1] [2] [3] . In certain areas of the world, the WHO estimates a high burden of HCV, especially in countries within Africa and the Eastern Mediterranean basin (highest prevalence in Egypt at 18%) [1, 3] . Approximately 21.3 million people living in Eastern Mediterranean countries are infected with HCV, which is comparable with the combined estimate of HCV carriers in the Americas and Europe [4, 5] . It is also in this region that HCV genotype 4 (HCV-4) is prevalent. In fact, HCV-4 comprises up to 80% of the HCV disease burden in many parts of the Middle East and Africa [3, 6] .
While pivotal trials with interferon-based therapies have demonstrated a high treatment response rate, defined as sustained virologic response (SVR; undetectable HCV-RNA 24 weeks after end-of-therapy), in patients with HCV genotypes 2 and 3, this has not been the experience in patients with HCV-4 [7] [8] [9] . Treatment response in HCV-4 has been comparable with that observed in HCV genotype 1 (∼40-50%).
Although previous studies have reported treatment data in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN + RBV) to be comparable to those with HCV-1, the results suggest a wide range of SVR rates, 28-71% [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . In addition, a majority of these studies have heterogeneous study designs and different patient populations, making it difficult to draw conclusions [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Furthermore, the association between SVR and host and viral factors in HCV-4 patients during treatment is unclear given conflicting results from published studies.
Very recently, triple therapy with PEG IFN + RBV and sofosbuvir has been approved by the Food and Drug Administration in the USA for the treatment of HCV-4 [19] . In Egypt, where the prevalence of HCV is the highest in the world and genotype 4 is predominant, the government price of sofosbuvir has been negotiated to 900 US dollars for a complete 12-week course of treatment [20] . In conjunction with decreased costs of monitoring with a 12-week regimen instead of 48 weeks, triple therapy has the potential to improve access and cure rates for people with HCV. However, this treatment option may remain elusive to patients in developing countries where the HCV-4 burden is high and funding for medications remains limited. Thus, PEG IFN + RBV may continue to be a mainstay of treatment.
Therefore, our aims are to systematically and quantitatively evaluate treatment outcome data and the influence of host and viral factors on virologic response in HCV-4 patients treated with PEG IFN + RBV.
Methods

Data sources and searches
We performed a comprehensive literature search in MEDLINE and EMBASE in November 2013 with the following search term: ('genotype 4'). Studies with non-English languages were included. We also conducted a manual search of abstracts using the term 'genotype 4' from annual international scientific meetings held between 2012 and 2013 by the American Association for the Study of Liver Diseases (AASLD), Digestive Disease Week (DDW), Asian Pacific Study of the Liver (APASL), and European Association for the Study of the Liver (EASL). In addition, we manually reviewed the bibliographies of published studies for relevant articles for inclusion into our study.
Study selection
We considered studies for inclusion based on the following characteristics: (i) original studies, (ii) inclusion of treatment-naive patients, (iii) minimum sample size of at least 25 HCV-4 patients, and (iv) treatment with PEG IFN + RBV. We excluded studies if study cohorts included patients with: hepatitis B, hepatitis D, or HIV coinfection or those with other concurrent liver diseases. Two of the authors (B. Yee and B. Zhang) independently reviewed the articles, and discrepancies were reviewed by another author (M. Nguyen) and resolved by consensus.
Data extraction
We designed a data abstraction form to collect data with the following information obtained from each study: study design, study type [randomized controlled trial (RCTs) vs. observational], intention-to-treat (ITT) analysis, country of origin, practice setting, collaboration, and baseline patient characteristics inclusive of ethnicity, age, sex, alanine transaminase (ALT), fibrosis, and HCV-RNA levels. Information on treatment characteristics was also collected: duration of treatment (48 vs. 24 weeks), IL28B gene polymorphisms, and presence and level of liver fibrosis/cirrhosis.
Statistical analysis
We performed statistical analyses to produce pooled event rates (overall SVR rate) with corresponding 95% confidence intervals (CIs) using random-effects (DerSimonian and Laird method) model and inverse variance method [21] . We assessed for study heterogeneity with χ 2 -based Cochrane Q-statistic with P-value up to 0.05 and I 2 at least 50% in adherence to the standards of quality for reporting meta-analysis from the Cochrane handbook [21] . We produced odds ratios (OR) and corresponding 95% CIs for subgroup analyses. Univariate and multivariate random-effects metaregression on study-level characteristics was also performed to explain any observed heterogeneity in our primary outcome, as well as identify any patient-level factors that may be associated with our primary outcome [21] [22] [23] . We assessed for potential publication bias graphically with a funnel plot of ln[OR] against its SE. Influence analysis with a one-study removal method to identify potential outliers contributing to our pooled estimate was conducted where appropriate. The graphs for funnel plots, with accompanying Egger's test, and influence analyses may be found in the supplemental pages. In studies with zero-cell counts, a fixed value of '0.5' was added to all cells of study results tables [21] . All statistical tests were two sided. All calculations were performed using Comprehensive Meta-Analysis, version 2 (Biostat, Englewood, New Jersey, USA), and STATA 11 (StataCorporation, College Station, Texas, USA) [22, 24, 25] .
Results
Literature search results
Our literature search identified 1798 studies (729 articles from MEDLINE and 1069 articles from EMBASE) and 14 648 abstracts from major liver society meetings held in 2012 and 2013. Eighty-four studies were closely evaluated for eligibility [10] [11] [12] [13] [14] [15] [16] 18, . Fourteen studies did not have extractable treatment outcomes data [26, 29, 36, 47, 50, 58, 61, 64, 74, 86, 87, 92, 100, 101] . Six were redundant [49, 51, 57, 68, 89, 99] and four were not relevant [30, 43, 60, 94] . Two studies did not contain original data [52, 98] . Three studies did not evaluate treatment-naive patients [31, 32, 97] , one study did not have at least 25 HCV-4 patients [33] , and three studies included patients coinfected with hepatitis B virus, HIV, or other liver diseases [44, 70, 82] . After conducting a comprehensive review, a total of 44 articles and seven abstracts met eligibility criteria and were included in the meta-analysis ( Fig. 1 ).
Study characteristics
There were 51 studies with a total of 11 102 HCV-4 patients included in the primary analysis (Table 1) [ 10-16,18,27,28,34,35,37-42,45,46,48,53-56,59,62,63,65-67, 69,71-73,75-81,83-85,88,90,91,93,95,96] . The majority of studies (40/51, 78%) originated from the Middle East [10-13, 15,16,18,27,28,34,35,37,40-42,45,46,53-56,59,62,63,66, 67,69,72,75,78,80,81,83-85,88,91,95] and Europe (9/51, 18%) [14, 38, 39, 65, 71, 76, 79, 93, 96] . One originated in Cameroon [77] and one multicenter study was conducted in 19 countries [73] . Most studies were performed in a university setting and had an ITT analysis. In all studies, the majority of patients were male. Mean age ranged from 38.2 to 57.1 years. All but one study included SVR in patients treated for 48 weeks [71] .
SVR rates overall and by study design Overall
In 51 studies with a total of 11 102 HCV-4 patients, the pooled SVR rate was 53% (CI: 50-55%) (Q-statistic = 269.20, P < 0.05; I 2 = 81.43) ( Fig. 2 ). Funnel plot and Egger's test showed no significant publication bias (P = 0.39) ( Supplementary Fig. 1a ). On influence analysis, our pooled event rate varied by no more than ∼ 1%, demonstrating the robustness of our estimate ( Supplementary Fig. 1b ).
RCT versus non-RCT studies
When comparing RCTs versus non-RCT studies, we observed a pooled SVR rate of 60% (CI: 53-68%) in the six RCTs [10, 13, 16, 18, 54, 93] compared with 52% (CI: 49-55%) in 45 non-RCTs [11,12,14,15,27,28,34,35,37-42, 45,46,48,53,55,56,59,62,63,65-67,69,71-73,75-81,83-85,88, 90,91,95,96] (Fig. 3 ). This finding was statistically significant with P equal to 0.043. Heterogeneity was observed in both subgroups (I 2 = 82.40 for non-RCT studies; I 2 = 48.72 for RCTs).
Prospective versus retrospective studies
Subgroup analysis by prospective and retrospective studies showed similar SVR rates: 53% (CI: 50-56%) in 43 prospective studies [10,11,13-16,18,27,28,34,38-42,46,48,53-56, 62,63,65-67,69,72,73,75-78,80,81,83,84,88,90,91,93,95,96] and 53% (CI: 46-59%) in eight retrospective studies [12, 35, 37, 45, 59, 71, 79, 85] . Significant heterogeneity was observed in both subgroup analyses with I 2 greater than 50% ( Fig. 4 ).
Random-effects meta-regression of study characteristics
Study characteristics of all 51 studies were explored on univariate and multivariate random-effects metaregression to explain the heterogeneity observed in our primary outcome and also quantify any residual heterogeneity. On univariate and multivariate analyses, no study characteristics were found to be significant predictors of heterogeneity in our pooled SVR rate ( Table 2) .
SVR rates by host and viral factors Lower versus higher viral load
Eleven studies with a total of 1130 patients [539 (48%) with lower viral load and 591 (52%) with higher viral load] had treatment outcomes directly comparing lower versus higher baseline viral load ( Supplementary Fig. 2a ) [11, 34, 54, 56, 62, 63, 67, 69, [76] [77] [78] .
SVR estimate was 67% (CI: 62-72%) in patients with lower viral load and 45% (CI: 35-54%) in patients with higher viral load. Although the definition of higher viral load varied across studies, ranging from a threshold of greater than 200 000 IU/ml to greater than 800 000 IU/ml, we observed a pooled OR of 3.05 (CI: 1.80-5.17, P < 0.001) favoring patients with lower baseline viral load. Significant heterogeneity was observed in our model (Q-statistic = 28.70, P < 0.05; I 2 = 65.16) ( Supplementary Fig. 2b and c).
Mild versus advanced/severe hepatic fibrosis
There were 14 studies with a total of 3116 patients [1580 (51%) mild fibrosis and 1536 (49%) severe fibrosis] that evaluated the influence of fibrosis on treatment response. Eleven studies used the METAVIR scoring system [11, 62, 63, 66, 67, 69, 76, 77, 79, 80, 95] , whereas three other studies used a different scoring system (Knodell, Ishak, or Scheuer) to classify patients as having either mild or severe fibrosis [42, 56, 78] .
Overall, SVR was 66% (CI: 60-72%) for patients with mild fibrosis and 39% (CI: 35-43%) for those with severe fibrosis. Compared with patients with severe fibrosis, patients with mild fibrosis were significantly more likely to obtain SVR, 3.17 (CI: 2.19-4.59, P < 0.001) (Q-statistic = 39.45, P < 0.05, I 2 = 67.05) ( Supplementary  Fig. 3a-c) .
In the 11 studies that evaluated levels of fibrosis with METAVIR scoring system [102] , there were a total of 3116 patients [1580 (51%) with mild fibrosis and 1536 (49%) with severe fibrosis] ( Supplementary Fig. 4a ) [17, 62, 63, 66, 67, 69, 76, 77, 79, 80, 95] . In this subgroup analysis, SVR in mild versus severe fibrosis was 65% (CI: 57-71%) and 38% (CI: 34-42%), respectively. In a direct comparison, patients with mild fibrosis were more likely to achieve SVR, OR 3.00 (CI: 1.98-4.56) (Q-statistic = 27.96, P < 0.05, I 2 = 64.23). In all but one study, mild fibrosis and severe fibrosis were defined as F0-F2 and F3-F4, respectivelythe study by Khairy et al. [66] defined mild fibrosis as F0-F1 and severe fibrosis as F2-F4. On influence analysis, our pooled OR increased by 12%, Fig. 4b and c) . By including patients with METAVIR score of F2 into the severe fibrotic group, this study may have diminished the effect size between mild and severe fibrosis.
IL28B CC versus CT/TT polymorphism
Nine studies with a total of 1893 patients [572 (30%) CC and 1321 (70%) CT/TT] assessed SVR in rs12979860 CC versus CT/TT ( Fig. 5a) 
IL28B TT versus GT/GG polymorphism
Five studies with a total of 751 HCV-4 patients [406 (54%) TT and 345 (46%) GT/GG] assessed SVR in rs8099917 TT compared with GT/GG (Fig. 5b) [27, 37, 42, 81, 88] .
SVR rates were 69% (CI: 59-77%) in TT and 33% (CI: 21-48%) in GT/GG patients. The OR of SVR was 5.21 (CI: 2.31-11.73, P < 0.001) in favor of patients with rs8099917 TT. Significant heterogeneity was observed in our model (Q-statistic = 17.85, P < 0.05, I 2 = 77.59).
Male versus female patients
Twenty-three studies with total of 3211 HCV-4 patients [2322 (72%) males and 889 (28%) females] included information on the influence of sex on SVR.
SVR in males was 54% (CI: 49-58%) and SVR in females was 54% (CI: 49-60%). We did not observe a significant difference in SVR between males and females with an Ragheb et al. [81] Mahmoud et al. [72] Khairy et al. [66] Omran et al. [78] Derbala et al. [41] El Raziky et al. [12] Abdo et al. [27] Monis et al. [75] Saad et al. [84] El Khayat et al. [10] Afifi and El-gohary [28] Shiha et al. [91] Esmat and Fattah [55] Derbala et al. [42] Al-Ashgar et al. [34] Farag et al. [54] Urquijo et al. [96] Antaki et al. [37] Pasha et al. [80] Shaker and Sadik [90] El-Shamy et al. [53] Papastergiou et al. [79] Marcellin et al. [73] Khattab et al. [69] Al-Enzi et al. [35] De Nicola et al. [39] Ibrahim et al. [63] Derbala et al. [45] Taha et al. [95] Khattab et al. [67] Moucari et al. [76] El Makhzangy et al. [11] Njouom et al. [77] López-Alonso et al. [71] Derbala et al. [46] Gad et al. [59] Derbala et al. [40] Hasan et al. [62] Mauss et al. [14] Kamal et al. [16] Kamal et al. [13] Kamal et al. [18] Asselah et al. [38] Karatapanis et al. [65] Shaker et al. [88] Saad et al. [83] Shahin et al. [85] Ahmed et al. [15] Stauber et al. [93] El Khayat et al. [10] Eskander et al. [54] Statistics for each study SVR was 70% (CI: 62-77%) and 49% (CI: 15-84%) in patients treated for 48 and 24 weeks, respectively. However, the difference in treatment response between these two groups did not reach statistical significance, OR 2.57 (CI: 0.58-11.34, P = 0.21) ( Supplementary Fig. 6 ).
Random-effects meta-regression of age and baseline ALT level
Although we did not have individual level data available for subgroup analyses of age and baseline ALT levels, there were summary statistics available (mean averages) for a random-effects meta-regression.
On univariate analysis of 38 studies that included mean age, we detected a trend for studies with older mean ages to be associated with lower SVR rates, β = − 0.04 (CI: − 0.07 to 0.0002, P = 0.05; I 2 residual = 79.1%; adjusted Ragheb et al. [81] Mahmoud et al. [72] Khairy et al. [66] R 2 = 11.3%) ( Fig. 6) . On a multivariate meta-regression analysis inclusive of mean age and proportion of patients with advanced fibrosis (as defined by each study), there was no association between age and SVR (β = − 0.002, P = 0.91). The negative association between increasing age and SVR we observed on univariate meta-regression could be explained by the fact that older patients tend to have more fibrosis than younger patients. Mahmoud et al. [72] Khairy et al. [66] Omran et al. [78] Derbala et al. [41] Abdo et al. [27] Monis et al. [75] Saad et al. [84] El Khayat et al. [10] Afifi and El-gohary [28] Shiha et al. [91] Esmat and Fattah [55] Derbala et al. [42] Al-Ashgar et al. [34] Farag et al. [54] Urquijo et al. [96] Pasha et al. [80] Shaker and Sadik [90] El Khayat et al. [10] El-Shamy et al. [53] Marcellin et al. [73] Khattab et al. [69] Eskander et al. [54] De Nicola et al. [39] Ibrahim et al. [63] Gad et al. [59] Kamal et al. [16] Taha et al. [95] Khattab et al. [67] Moucari et al. [76] El Makhzangy et al. [11] Njouom et al. [77] López-Alonso et al. [71] Derbala et al. [46] Derbala et al. [45] Derbala et al. [40] Hasan et al. [62] Mauss et al. [14] Shahin et al. [85] Antaki et al. [37] El Raziky et al. [12] Papastergiou et al. [79] Al-Enzi et al. [35] Kamal et al. [13] Kamal et al. [18] Asselah et al. [38] Karatapanis et al. [65] Stauber et al. [93] Shaker et al. [88] Saad et al. [83] Ahmed et al. [15] 0 Retrospective SVR rates in prospective versus retrospective studies. CI, confidence interval; SVR, sustained virologic response. On univariate analysis of 27 studies with mean baseline ALT levels, we observed a trend for studies with higher mean baseline ALT levels to have a positive association with higher SVR rates, β = 0.004 (CI: − 0.0007 to 0.01, P = 0.09; I 2 residual = 78.1%; adjusted R 2 = 17.38%) ( Supplementary Fig. 7) .
Publication bias
In all our subgroup analyses, we did not observe any publication bias (no significant asymmetry on funnel plot and accompanying Egger's tests with P > 0.05) ( Supplementary   Fig. 1a , Supplementary Fig. 2b, Supplementary Fig. 3b , Supplementary Fig. 4b, Supplementary Fig. 5b ).
Discussion
In our current meta-analysis, which included 51 studies with a total of 11 102 HCV-4 patients treated with PEG IFN + RBV, we observed a pooled SVR rate of 53% (CI: 50-55%). This estimate remained robust on influence analysis and no publication bias was observed. In subgroup analyses by study characteristics, pooled SVR rates Favors CT/TT favors CC Lower limit
Upper limit
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Ragheb et al. [81] Derbala et al. [41] Derbala et al. [42] Shaker et al. [88] Asselah et al. [38] De Nicola et al. [39] Antaki et al. [37] Pasha et al. [80] Abdo et al. [27] 29 Derbala et al. [42] Shaker et al. [88] Antaki et al. [37] Abdo et al. [27] 25.556 were the same in retrospective and prospective studies, whereas there was a significantly lower pooled SVR rate in non-RCTs compared with RCTs: 52% (CI: 49-55%) versus 60% (CI: 53-68%), respectively (P = 0.043). However, on multivariate random-effects metaregression inclusive of study nature (retrospective vs. prospective), country of origin (European vs. Eastern Mediterranean basin), and ITT versus non-ITT analysis, we did not find the same significant association between SVR rate and study design (non-RCTs vs. RCTs, P = 0.16). As a random-effect meta-regression is a more conservative approach for exploring observed and residual heterogeneity in a pooled estimate, the difference in SVR rates between non-RCTs and RCTs in our subgroup analysis was most likely confounded by the underlying differences in our included study populations.
Currently, there are two published meta-analyses on HCV-4 patients treated with PEG IFN + RBV that evaluated pooled treatment data [6, 23] . In their studies, Aljumah and Murad and Khuroo and colleagues observed pooled SVR rates of 51 and 55%, respectively, which was similar to our finding (53%). However, both studies were limited by small sample sizes; included only five [6] or six [17] RCTs only; and did not include subgroup analyses on host and viral factors on SVR. In contrast, our study included a large number of diverse studies (six RCTs and 45 non-RCTs studies, n = 11 102) and also evaluated the influence of host and viral factors on SVR rates in HCV-4 patients.
On the basis of pivotal studies, SVR is selectively higher in patients with milder forms of fibrosis [7, [103] [104] [105] .
Although most of the literature note this positive link, there are some studies with negative findings [63, 66, 76, 77] . However, these negative studies often have heterogeneous study designs, small sample sizes and variable patient populations. In our subgroup analysis, we found a favorable SVR response in patients with mild versus severe fibrosis, OR 3.17 (CI: 2.19-4.59, P < 0.001), across studies with different scoring systems, and also in studies using METAVIR system only, OR 3.00 (CI: 1.98-4.56, P < 0.001). Our finding is consistent with previous studies that established a relationship between severe fibrosis with lower SVR rates and poorer clinical outcomes [106] [107] [108] [109] [110] .
Another established determinant of treatment response is baseline viral load, with patients starting with a lower baseline HCV-RNA having a greater likelihood of achieving SVR [7, 103, 105] . In our study, we found a similar association between lower baseline viral load and higher SVR rates than those with higher viral load, OR 3.05 (CI: 1.80-5.17, P < 0.001). Although the threshold for higher viral load varied across studies (ranging from > 200 000 to > 800 000 IU/ml), our pooled OR did not change by more than 18% on influence analysis.
In regards to IL28B polymorphism, based on numerous genome-wide association and human subject studies, investigators have established an important link between common polymorphisms and SVR [39, 42, 111, 112] . In our subgroup analyses, which included 1893 HCV-4 patients with IL28B data, we found a favorable association between SVR and rs12979860 CC genotype versus CT/TT, OR 4.70 (CI: 2.87-7.69, P < 0.001), and between SVR and rs8099917 TT genotype versus GT/GG, OR 5.21 (CI: 2.31-11.73, P < 0.001). Our findings are consistent with established studies that have shown a strong link between certain IL28 polymorphisms and high SVR rates [39, 42, 112] .
Although the majority of the literature shows no difference in SVR rates between sexes, a study by Kamal and colleagues that included a total of 279 HCV-4 patients [145 (52%) males and 134 (48%) females] observed a significantly higher SVR in females versus males, OR 2.65 (CI: 1.63-4.31, P < 0.001) [18] . However, it is difficult to draw conclusions from one study among many others that have not found a positive association. In contrast, many of these negative studies had variable study designs and included small numbers of female individuals. In our subgroup analysis, inclusive of 23 studies with direct comparison between sexes, with a total of 3211 HCV-4 patients [2322 (72%) males and 889 (28%) females], we did not observe a significant difference in SVR rates between the two sexes. The ratio of males to females likely demonstrates a male treatment bias as the frequency of HCV-4 is similar for both sexes based on several epidemiological studies [113] [114] [115] .
Currently, the optimal treatment duration for PEG IFN + RBV in HCV-4 patients is unclear with few published studies on this topic. In the only two studies with direct comparison between 48 and 24 weeks of treatment, the results have been conflicting. One study by El Khayat and colleagues that included 44 patients treated for 48 weeks and 43 patients treated for 24 weeks, respectively, found no difference in SVR rates, OR 1.16 (CI: 0.46-2.93 P = 0.76), whereas another study by Kamal and colleagues that included twice as many patients in their sample size (96 patients treated for 48 weeks, 96 patients treated for 36 weeks, and 95 patients treated for 24 weeks) found a significant difference in SVR rates, OR 5.26 (CI: 2.84-9.76, P < 0.001), in favor of 48 versus 24 weeks [10, 18] . Several differences may explain these findings: Kamal and colleagues included patients with a higher viral load (mean 2.8 × 10 6 IU/ml in both cohorts) than patients in the study by El Khayat and colleagues (mean viral load of 144 640 IU/ml in 48-week and 135 490 IU/ml in 24-week cohorts) and patients in the study by Kamal and colleagues were treated with PEG IFN α-2b, whereas patients in the study by El Khayat and colleagues were treated with PEG IFN α-2a [16, 24] . In our subgroup analysis of these two studies, we found no significant difference in SVR rates between 48 and 24 weeks of treatment, OR 2.57 (CI: 0.58-11.34, P = 0.21). On the basis of the limited sample size of patients and included studies in our subgroup analysis, this analysis is an underpowered comparison and additional research is needed to define the optimal treatment duration for HCV-4 with PEG IFN + RBV.
Although we did not have individual patient-level data available for age and baseline ALT levels, we were able to collect study-level summary statistics for these factors (mean averages). On univariate random-effects metaregression, we detected a trend for studies with older mean age to be associated with lower SVR rates, β = − 0.04 (CI: − 0.07 to 0.0002, P = 0.05), and a trend for studies with higher mean baseline ALT levels to be associated with higher SVR rates, β = 0.004 (CI: − 0.0007 to 0.01, P =0.09). Although our data suggests associations between age and SVR rates and baseline ALT levels and SVR rates, additional studies are needed to further explore these observations as we cannot make firm conclusions on the basis of summary statistics alone.
Although our meta-analysis included a large number of studies and patients, it is not without limitations. One limitation of our study is the heterogeneity of our data given our broad inclusion criteria, which captured many studies of different study and patient characteristics. However, we accounted for this by estimating effect sizes from random-effects modeling and subgroup analyses by various study and patient characteristics. We also attempted to explain the heterogeneity we detected by performing univariate and multivariate random-effects meta-regression, which were more conservative analyses than subgroup analyses. Furthermore, influence analyses and funnel plots with accompanying Egger's tests were performed to identify any potential bias or outliers in our data, which we did not find. We also sought to minimize any publication bias by performing a comprehensive literature review from two major databases (MEDLINE and EMBASE), a manual search of abstracts in the last 2 years in four major international scientific journals, and a manual search for relevant articles in the bibliographies of published studies.
In summary, our study is a comprehensive and systematic evaluation of pooled SVR data in HCV-4 patients treated with PEG IFN + RBV across multiple studies of different study designs and patient characteristics. Overall, we observed a pooled SVR rate of 53% in our patient population and found an association with SVR with mild fibrosis, lower baseline viral load, and favorable IL28B polymorphisms (rs12979860 CC and rs8099917 TT genotypes).
